AzTrials
AzTrials

Chronic Knee PainNCT06514755

Sequential Genicular Nerve Ablation Prior to Geniculate Artery Embolization in Knee Pain

A study testing GNA followed by GAE and GAE alone in people with Chronic Knee Pain and Osteoarthritis, run by Zagazig University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to evaluate whether performing genicular nerve ablation (GNA) before geniculate artery embolization (GAE) improves pain relief and knee function in patients with chronic knee pain. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Chronic Knee Pain, Osteoarthritis
What is being tested?
GNA followed by GAE and GAE alone
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
38 participants
Where
1 siteEgypt
Study dates
29 Sep 2024to 30 Aug 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults aged 18 to 80 years.
  • Diagnosed with chronic knee pain refractory to conservative treatment.
  • Able to provide informed consent.
  • Agree to follow the study procedures and attend follow-up visits.

Who cannot join

  • Contraindications to GNA or GAE procedures (e.g., allergy to local anesthetics, active infection at the procedure site).
  • Recent knee surgery within the last six months.
  • Severe comorbid conditions that may interfere with the study outcomes (e.g., rheumatoid arthritis, other severe autoimmune diseases).
  • Current participation in another clinical trial that could interfere with the outcomes of this study.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Zagazig University, Faculty of Medicine

    Zagazig, 44519

Other trials in Egypt

About this study

Official title: Sequential Genicular Nerve Ablation Prior to Geniculate Artery Embolization in Knee Pain Management: A Randomized Controlled Trial

The goal of this clinical trial is to evaluate whether performing genicular nerve ablation (GNA) before geniculate artery embolization (GAE) improves pain relief and knee function in patients with chronic knee pain. The main questions it aims to answer are:

  • Does performing GNA prior to GAE enhance pain relief, as measured by the Visual Analog Scale (VAS), at 3 months post-procedure?
  • Does the sequential approach improve knee function as assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)?
Read more

Study investigators will compare two groups to see if the sequential approach (GNA followed by GAE) provides better outcomes compared to GAE alone.

Participants will:

  • Undergo either sequential GNA followed by GAE or GAE alone
  • Have their knee pain and function assessed at baseline, 1 month, 3 months, and 6 months post-procedure
  • Complete a structured patient satisfaction questionnaire (PSQ) at 3 months post-procedure
  • Be monitored for procedure-related adverse events up to 6 months post-procedure,
Read the detailed description

Background:

Chronic knee pain is a prevalent condition affecting a significant portion of the population, often leading to reduced quality of life and functional impairment. Current treatment options include genicular nerve ablation (GNA) and geniculate artery embolization (GAE). However, the optimal sequence of these interventions remains unclear.

Rationale:

The rationale for investigating the sequence of genicular nerve ablation (GNA) followed by geniculate artery embolization (GAE) lies in potentially optimizing pain relief and functional outcomes while ensuring patient safety and satisfaction. GNA aims to interrupt pain transmission from the genicular nerves to the central nervous system, while GAE targets the blood supply to the inflamed synovium, reducing inflammation and pain. Understanding whether performing GNA prior to GAE offers superior pain relief, functional improvement, and patient satisfaction compared to GAE alone is crucial for optimizing treatment protocols and guiding clinical practice.

Objectives:

  1. Primary Objective:
  • Evaluate whether performing GNA prior to GAE enhances pain relief, as measured by the Visual Analog Scale (VAS), at 3 months post-procedure.
  1. Secondary Objectives:
  • Evaluate changes in knee function using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), a validated scoring system specifically designed for osteoarthritis.
  • Monitor and document any procedure-related adverse events to compare the safety profiles of both techniques.
  • Evaluate patient satisfaction using the structured Patient Satisfaction Questionnaire (PSQ).

Study Design:

This study is a randomized controlled trial (RCT) aimed at evaluating the effectiveness of sequential GNA followed by GAE versus GAE alone in managing chronic knee pain. Eligible patients will be randomly allocated to one of the two treatment groups. Given the specific nature of the interventions, it may not be possible to blind participants or operators; however, to minimize potential bias, outcome assessors will be blinded to the treatment assignments.

Interventions:

  1. Sequential Genicular Nerve Ablation (GNA) followed by Geniculate Artery Embolization (GAE): Participants will undergo GNA targeting genicular nerves followed by GAE targeting geniculate arteries. Ablation parameters and embolization procedures will be standardized to ensure consistency across interventions.
  2. Geniculate Artery Embolization (GAE) Alone: Participants assigned to this group will receive GAE without prior GNA. The embolization procedure will follow standard protocols to target the geniculate arteries effectively.

Outcomes:

  1. Primary Outcome
  • Reduction in Knee Pain; this measure assesses the change in knee pain as reported by participants using the Visual Analog Scale (VAS). A lower score indicates less pain, signifying an improvement.

Secondary Outcomes:

  • Improvement in Knee Function; Assessed by changes in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores, which measure pain, stiffness, and physical function of the knee and hip joints. A lower WOMAC score indicates better joint function.
  • Incidence of Procedure-Related Adverse Events; monitoring and recording any adverse events related to the genicular nerve ablation procedures.
  • Patient Satisfaction with the Procedure; measured using a structured patient satisfaction questionnaire (PSQ) to gauge participants' satisfaction with the pain relief and overall experience of the procedure.

Follow-Up: Participants will be closely monitored post-procedure with scheduled follow-up visits at 1 week, 1 month, 3 months, and 6 months. These visits will include clinical assessments, pain evaluations, functional tests, and documentation of any adverse events.

Conclusion: This study aims to provide valuable insights into the effectiveness, safety, and patient satisfaction of performing genicular nerve ablation prior to geniculate artery embolization in the management of chronic knee pain. By rigorously evaluating these techniques, the findings will inform clinical decision-making, optimize treatment strategies, and pave the way for future research aimed at enhancing outcomes for patients suffering from chronic knee pain.

Being tested
GNA followed by GAE, GAE alone
Keywords
Genicular Nerve Ablation, Geniculate Artery Embolization, Knee Function, Patient Satisfaction
Medical subject headings
Osteoarthritis, Patient Satisfaction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • GNA followed by GAEProcedure or surgery

    Participants in the experimental arm will undergo genicular nerve ablation (GNA), a minimally invasive procedure targeting the genicular nerves to interrupt pain transmission. One month after undergoing GNA, participants will receive geniculate artery embolization (GAE), which targets the geniculate arteries to reduce inflammation and pain.

  • GAE aloneProcedure or surgery

    Participants in the active comparator arm will receive geniculate artery embolization (GAE) alone, a minimally invasive procedure targeting the geniculate arteries to reduce inflammation and pain, without prior genicular nerve ablation (GNA).

Study groups in NCT06514755
Study groupRoleWhat they receive
Sequential GNA Followed by GAEExperimentalParticipants in this group will undergo genicular nerve ablation (GNA), followed by geniculate artery embolization (GAE) one month later. The GNA procedure will target the genicular nerves responsible for knee pain, and the GAE procedure will target the geniculate arteries to reduce inflammation and pain. The sequence is designed to optimize pain relief and functional outcomes.
Receives: Procedure: GNA followed by GAE
GAE AloneActive comparatorParticipants in this group will receive geniculate artery embolization (GAE) alone, without prior genicular nerve ablation (GNA). The GAE procedure will target the geniculate arteries to reduce inflammation and pain. This arm serves as the control to compare the effectiveness and safety of the sequential GNA followed by GAE intervention.
Receives: Procedure: GAE alone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Reduction in Knee Pain

    This outcome measures the change in knee pain as reported by participants using the Visual Analog Scale (VAS). A lower score indicates less pain, signifying an improvement.

    Measured: 3 months post-procedure

Secondary outcomes (3)
  1. Improvement in Knee Function

    Assessed by changes in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores, which measure pain, stiffness, and physical function of the knee and hip joints. A lower WOMAC score indicates better joint function.

    Measured: Assessed at 1 month, 3 months, and 6 months post-procedure

  2. Incidence of Procedure-Related Adverse Events

    Monitoring and recording any adverse events related to the genicular nerve ablation procedures

    Measured: From the time of procedure up to 6 months

  3. Patient Satisfaction with the Procedure

    Measured using a structured patient satisfaction questionnaire (PSQ) to gauge participants' satisfaction with the pain relief and overall experience of the procedure.

    Measured: 3 months post-procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jul 2024
  2. Study start29 Sep 2024
  3. Primary completion30 Mar 2025
  4. Study completion30 Aug 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants will be randomly assigned to one of two groups: one undergoing sequential genicular nerve ablation (GNA) followed by geniculate artery embolization (GAE), and the other receiving GAE alone.
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
38 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06514755
Sponsor's protocol ID
GNA-GAE-KP
Status last verified
Sep 2026
First submitted
17 Jul 2024
Last updated
23 Sep 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: At this time, there is no plan to share individual participant data (IPD) with other researchers. This decision is based on considerations related to patient confidentiality, data privacy concerns, and the absence of a current infrastructure for secure data sharing. The primary results of the study will be published in peer-reviewed journals and presented at scientific conferences, ensuring that the findings are accessible to the broader research community.

Questions about this trial

What is this clinical trial studying?

A study testing GNA followed by GAE and GAE alone in people with Chronic Knee Pain and Osteoarthritis, run by Zagazig University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Reduction in Knee Pain (time frame: 3 months post-procedure). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in